Search results
Combined flu and Covid vaccine 'triggers stronger immune response'
Daily Express· 30 minutes agoA combined jab for flu and Covid triggered a stronger immune response than separate single vaccines, according to data released by Moderna. The US pharmaceutical firm’s Spikevax ...
Experimental mRNA vaccines gain steam with promising cancer trial results
Semafor via Yahoo News· 7 days agoInsights from TIME, The Washington Post, MIT Technology Review The News Pharmaceutical giants ...
Hunter Biden’s trial nears end, EU elections see far-right gains and Celtics win NBA Finals Game 2
The Yodel via Yahoo News· 5 hours agoGet caught up on this morning’s news: Hunter Biden’s trial nears end, Celtics win NBA Finals Game 2...
Promising trial data for Moderna-Merck skin cancer vaccine sends stock rising
Quartz· 7 days agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs
FierceBiotech· 3 days agoModerna’s methylmalonic acidemia candidate, mRNA-3705, will be developed under the FDA’s START pilot...
Apple to announce AI features at Monday’s WWDC; what to know, how to watch
WSOC-TV Charlotte· 1 hour agoApple is expected to announce Monday at its annual Worldwide Developers Conference that it will...
Graco and A.O. Smith Boast High Profit, Low Debt
GuruFocus.com via Yahoo Finance· 23 minutes agoMueller Industries did best, up 38%. Cal-Maine Foods (NASDAQ:CALM) also did well, returning 26% including dividends. Diodes Inc. (NASDAQ:DIOD) was a loser, dropping 23%. Moderna< ...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Moderna, Inc. -...
Morningstar· 3 days agoNEW YORK, June 7, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Moderna, Inc. ("Moderna" or the "Company") (NASDAQ ...
Moderna Files With FDA for Updated Covid Shot
Market Watch· 3 days agoPublished: June 7, 2024 at 11:15 a.m. ETShareResizeBy Dean SealAbout Dow Jones NewswiresDow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Zacks via Yahoo Finance· 4 hours agoPfizer plans to seek approval from the FDA for the expanded use of Abrysvo for adults 18 years and...
